Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT04142125

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04142125
Other papers using this trial's data
  • Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease Stroke, 2025-02 DOI, PubMed 39781748

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04142125. Randomized; single masking; primary purpose treatment. Start 2020-02-03 (actual); primary completion 2023-09-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
Condition
Intracranial Atherosclerotic Disease
Intervention (Drug)
Rivaroxaban 2.5 Mg Oral Tablet bid
Intervention (Drug)
Acetylsalicyclic acid 81 mg tablet qd
Lead sponsor
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct04142125
Content hash
c032eb137b33793be9306b06e71ae7a785f69da06e5ac0e60ff9da08d1327509